http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Exact Sciences Designated a Great Place to Work-Certified™ Company in 2019
-
Exact Sciences to host annual meeting, second-quarter 2019 results webcasts and calls
-
Exact Sciences to participate in June investor conferences
-
Exact Sciences Advances Pipeline Capabilities with Mayo Clinic
-
Exact Sciences Presents New Data Reinforcing Performance of Cologuard®
-
Exact Sciences to participate in May investor conferences
-
First-quarter revenue and Cologuard test volume increased 79 percent to $162 million and 334,000, respectively
-
Exact Sciences schedules first-quarter 2019 earnings call
-
Kathleen Sebelius Appointed to Exact Sciences Board
-
Exact Sciences to participate in March investor conferences
-
Cologuard Helps Screen Two Million People for Colorectal Cancer
-
Total 2018 revenue increased 71 percent to $454 million, and 934,000 people were screened with Cologuard
-
Exact Sciences schedules fourth-quarter, full-year 2018 earnings call
-
Exact Sciences to report $454-455M in total revenue, 71-percent growth for 2018
-
Exact Sciences to participate in J.P. Morgan Healthcare Conference
-
Exact Sciences to participate in two November investor conferences
-
Cologuard® revenue increased 63 percent to $118 million, and Cologuard test volume grew 49 percent to 241,000 during third quarter
-
Exact Sciences (EXAS) Announces Acquisition of Biomatrica
-
Exact Sciences Strengthens Pipeline Capabilities with Acquisition of Biomatrica, a Leading Provider of Biological Sample Preservation Technology
-
Exact Sciences schedules third-quarter 2018 earnings call
-
Exact Sciences to participate in September investor conferences
-
Exact Sciences to host conference call and webcast to discuss its Cologuard co-promotion agreement with Pfizer
-
Exact Sciences (EXAS) Announces U.S. Promotional Agreement with Pfizer (PFE) for Cologuard
-
Exact Sciences and Pfizer Enter into U.S. Promotion Agreement for Cologuard®
-
Green Bay Packers and Cologuard Launch "Crossing the 50" Colon Cancer Awareness Campaign
-
Exact Sciences to participate in Canaccord Genuity Growth Conference
-
Tom Lehman Joins Forces with Fight Colorectal Cancer to Raise Awareness of Nation's Second-Leading Cause of Cancer Deaths
-
Cologuard® revenue increased 78 percent to $103 million during second quarter
-
Exact Sciences to host annual meeting, second-quarter 2018 results webcasts and calls
-
Nurse Practitioners are Critical Source of Colorectal Cancer Screening Information for Patients, Survey Shows
-
Cologuard Challenge Expands to AmFam Championship Urging PGA TOUR Champions Fans to Get Screened for Colon Cancer
-
Exact Sciences (EXAS), Mayo Clinic Researchers Identify Blood-Based DNA Biomarker Panel to Accurately Diagnose HCC
-
Exact Sciences, Mayo Clinic Researchers Identify Blood-Based DNA Biomarker Panel to Accurately Diagnose Hepatocellular Carcinoma
-
Exact Sciences to participate in June investor conferences
-
Exact Sciences (EXAS) Says It Applauds ACS's Updated Colorectal Cancer Screening Guidelines to Include People Age 45-49
-
Exact Sciences Applauds American Cancer Society's Updated Colorectal Cancer Screening Guidelines to Include People Age 45-49
-
Exact Sciences Applauds American Cancer Society's Updated Colorectal Cancer Screening Guidelines to Include People Age 45-49
-
Vince Lombardi Cancer Foundation and Exact Sciences Team Up to Fight Colon Cancer
-
Exact Sciences to participate in two investor conferences during May
-
Cologuard® revenue and completed tests increased 87 percent to $90.3 million and 186,000
-
Exact Sciences schedules first-quarter 2018 earnings call
-
Exact Sciences (EXAS) Announces Mark Stenhouse as President, Cologuard
-
Mark Stenhouse to join Exact Sciences as President, Cologuard
-
Harry Connick, Jr. and Wife and Cancer Survivor Jill Connick Team Up to Urge People 50 and Older to Get Screened for Colon Cancer
-
Mayo Clinic's Dr. Paul Limburg to join Exact Sciences medical leadership
-
Exact Sciences to participate in March investor conferences
-
Exact Sciences Corp. (Nasdaq: EXAS) to Ring The Nasdaq Stock Market Opening Bell Remotely from Tucson, Arizona
-
Cologuard® revenue increased 168 percent to $266 million
-
Exact Sciences schedules fourth-quarter, full-year 2017 earnings call
-
Exact Sciences to participate in Leerink Partners 7th Annual Global Healthcare Conference

